Artelo Biosciences (ARTL)

• Market cap: $2.7M
• 1 day: -1.67%
• 5 days: 14.65%
• 1 month: 0.24%
• 3 months: -17.06%
• 6 months: -19.85%
• Year to date: -12.50%
• 1 year: -27.74%
• 5 years: -94.52%
• 10 years: -98.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Employees: 6

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

43% more capital invested

Capital invested by funds: $25.6K [Q3] → $36.6K (+$10.9K) [Q4]

20% more funds holding

Funds holding: 5 [Q3] → 6 (+1) [Q4]

0.37% more ownership

Funds ownership: 0.7% [Q3] → 1.07% (+0.37%) [Q4]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 424% upside
• Avg. target: $5.50 477% upside
• High target: $6 529% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target	529% upside $6	Buy Maintained	2 Apr 2025
HC Wainwright & Co. Vernon Bernardino 18% 1-year accuracy 13 / 71 met price target	424% upside $5	Buy Reiterated	4 Mar 2025